Diligence memo · auto-generated · as of July 2, 2026
Gaingels Alto Pharmacy 2023 LLC
Gaingels Alto Pharmacy 2023 LLC looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Gaingels Alto Pharmacy 2023 LLC operates in Biotech / Pharma, based in BURLINGTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Gaingels Alto Pharmacy 2023 LLC has raised $525K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $525K on 2023-06-27.
Most recent recorded round closed around 2023-06-27.
Valuation (modeled)modeled
Provath models Gaingels Alto Pharmacy 2023 LLC at approximately $4.4M (range $287K–$20M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.10× the median modeled value of Pre-Seed Biotech / Pharma companies in 2022–2024 (28 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 3.0 yr ago; this sector typically re-raises about every 15 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 23% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 22% of those peers.
Closest niche peers: Gaingels Oct Bio LLC, Gaingels Alto Pharmacy LLC, Pyros Pharmaceuticals, Inc., Allander Biotechnologies, Inc., CyMon Bio, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.